SupraDiag | HES⁠-⁠SO University of Applied Sciences and Arts Western Switzerland

Engineering & ArchitectureSupraDiag

Point-of-care (POC) in-vitro diagnostic assays should measure biomarkers or small molecules in the blood quantitatively and not only qualitatively. However, today’s assays poorly meet this demand due to the multiple preparation steps required: blood filtering, mixing of reagents, etc. Moreover, they are limited to single-point measurements.

This project aims at synthetizing and exploring a novel type of molecular biosensors that could trigger a paradigm shift in POC diagnostics. These supramolecular biosensors are designed to undergo a conformational change in presence of a specific biomarker, which results in the modulation of an optical signal. This enables the quantification of biomarkers in body fluids without the requirement for sample preparation, which greatly simplify the assays. Furthermore, these supramolecular biosensors offer the possibility of continuously monitoring biomarkers or small molecules in the blood. The concept was demonstrated by synthetizing a functional supramolecular biosensor for the anti-cancer drug methotrexate. 


Dr. Jean-Manuel Segura

HES⁠-⁠SO Rectorate
Route de Moutier 14
2800 - Delémont
T +41 58 900 00 00 - F +41 58 900 00 01
By continuing to browse this site, you agree to the use of cookies to improve your user experience and to provide website statistics.
Read the legal notice ok